MAPT and supranuclear palsy, progressive, 1: In conclusion, plasma pTau217 levels, as a proxy for both Aβ and tau pathology, represent a scalable, cost-effective, and non-invasive marker of AD pathology across the PD-cognitive spectrum, PSP/CBS, and MCI/CU populations, to timely identify individuals at risk of cognitive deterioration.